Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1096 How Manage Multiple Small Bowel Neuroendocrine Tumors?

Introduction: Multiple small bowel neuroendocrine tumors (SB-NET) represent 30% of SB-NET.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Pasquet A

Authors: Pasquer A, Walter T, Hervieu V, Forestier J, Scoazec J,

Keywords: small bowel, surgery, prognosis, multiple,

#1081 High Thyrocalcitonin Serum Level in Neuroendocrine Tumors: Characteristics, Prognosis and Interest in Follow-Up?

Introduction: Thyrocalcitonin (TCT) is usually associated with medullary thyroid cancer. However, some neuroendocrine tumors (NETs) have also high serum TCT levels.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Nozière C, Chardon L, Lombard-Bohas C, Goichot B, Hervieu V,

Keywords: thyrocalcitonin,

#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?

Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Dussol A, Joly M, Hervieu V, Forestier J, Lombard-Bohas C,

Keywords: gemox, alkylating agent, MGMT,

#1032 Clinico-Biological and Histological Predictive Factors and Markers of Response to Everolimus in Neuroendocrine Tumors

Introduction: Several systemic treatments are available for metastatic neuroendocrine Tumors (NETs), including everolimus, but there is no predictive factor of response to these treatments.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Walter T

Authors: Benslama N, Bollard J, Vercherat C, Roche C, Hervieu V,

Keywords: neuroendocrine tumors, everolimus, markers, p-p70S6K,

#748 O6-Methylguanine-DNA Methyltransferase Deficiency in Neuroendocrine Tumors and Correlation with Response to Alkylating Agents (Temozolomide, Streptozotocin, Dacarbazine)

Introduction: Low O6-methylguanine-DNA methyltransferase (MGMT) expression is predictive of response to alkylants in some tumor types.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Van Brakel B, Walter T, Hervieu V, Forestier J, Chayvialle J,

Keywords: MGMT,